Celltrion’s Subcutaneous Infliximab Lands On Big PBM Formulary List
Korean Firm Is Also Offering Temporary Patient Support Initiatives To Drive Uptake
One down, two more to go. Celltrion seals a formulary deal with one of the top three PBMs in the US for its subcutaneous infliximab product Zymfentra.
